- Home
- BCLI vs MNDO Comparison
BCLI vs MNDO Comparison
Compare BCLI & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- MNDO
- Stock Information
- Founded
- BCLI 2000
- MNDO 1995
- Country
- BCLI United States
- MNDO Israel
- Employees
- BCLI N/A
- MNDO N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- MNDO EDP Services
- Sector
- BCLI Health Care
- MNDO Technology
- Exchange
- BCLI Nasdaq
- MNDO Nasdaq
- Market Cap
- BCLI 25.0M
- MNDO 40.5M
- IPO Year
- BCLI N/A
- MNDO 2000
- Fundamental
- Price
- BCLI $2.43
- MNDO $1.97
- Analyst Decision
- BCLI Strong Buy
- MNDO
- Analyst Count
- BCLI 1
- MNDO 0
- Target Price
- BCLI $30.00
- MNDO N/A
- AVG Volume (30 Days)
- BCLI 77.4K
- MNDO 20.5K
- Earning Date
- BCLI 11-12-2024
- MNDO 11-05-2024
- Dividend Yield
- BCLI N/A
- MNDO 12.12%
- EPS Growth
- BCLI N/A
- MNDO N/A
- EPS
- BCLI N/A
- MNDO 0.25
- Revenue
- BCLI N/A
- MNDO $21,912,000.00
- Revenue This Year
- BCLI N/A
- MNDO N/A
- Revenue Next Year
- BCLI N/A
- MNDO N/A
- P/E Ratio
- BCLI N/A
- MNDO $7.88
- Revenue Growth
- BCLI N/A
- MNDO 2.58
- 52 Week Low
- BCLI $1.95
- MNDO $1.70
- 52 Week High
- BCLI $11.85
- MNDO $2.28
- Technical
- Relative Strength Index (RSI)
- BCLI 36.93
- MNDO 52.46
- Support Level
- BCLI $1.97
- MNDO $1.95
- Resistance Level
- BCLI $2.24
- MNDO $2.00
- Average True Range (ATR)
- BCLI 0.37
- MNDO 0.05
- MACD
- BCLI 0.03
- MNDO -0.01
- Stochastic Oscillator
- BCLI 26.26
- MNDO 15.79
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.